Refine by
Clinical Response Articles & Analysis
105 news found
Earlier in his career, he held various positions at Mallinckrodt (formerly Ikaria Inc.), where he was responsible for the North America franchise of several key products, as well as at Baxter, where he spent six years managing business operations and global analytics. ...
Clinical Trial Manager roles are growing 32% faster than the national average. This job is undeniably rewarding but requires a high level of expertise and a knack for research. A clinical trial manager is responsible for many tasks, including overseeing everything from creating a valid test to its administration, recruitment, ...
Efficient leadership plays a huge role in bringing a clinical trial to fruition. Pharmaceutical companies are not immune to making mistakes and facing failures. ...
About the webinar 2020/21 led to significant clinical trial innovation in clinical trials in response to the Covid-19 pandemic with 2022 providing key insights, projects and lessons in the wider clinical trials space. 2023 will see these lessons merge with long-term trends and the lessons from important pilot programs to see ...
ByStatsol
“But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines. By predicting human clinical response much earlier in the drug development cycle, we can help pharmaceutical companies shave years off drug ...
The study titled, “Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes,” assessed the relationship between cardiac filling pressures (a commonly used surrogate to assess blood volume) and total blood volume (TBV) measurement using Daxor’s BVA-100 blood test between sexes and left ventricular ejection fraction (LVEF), key clinical determinants ...
In the MANIFEST study, changes in biomarkers correlated with improvements in clinical measures of treatment success (SVR35, TSS50 and hemoglobin increases indicative of improved anemia), suggesting a potential disease-modifying effect of pelabresib. ...
The studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected. ...
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. ...
This is paving the way for improving patient care as ePROMs can be used to monitor patients with reported health conditions coming directly from the patient, so caregivers and clinicians can know about the patient’s health concerns outside the clinical setting. Methods for collecting patient information involve questionnaire-based assessments with branching logic and ...
Endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and Egnyte, the secure platform for content collaboration and governance, today announced that Endpoint Clinical has partnered with Egnyte, providing a Google Cloud-compliant platform to establish a secure file server that can ...
STALICLA SA, a precision neuroscience clinical stage biotech advancing the first precision medicine platform for patients with Neurodevelopmental Disorders, has in-licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. ...
BySTALICLA
Pursuant to the terms of the agreement, STALICLA will be responsible for the clinical development in the NDD field, and the parties will cooperate on regulatory activities to secure approval of the product. ...
BySTALICLA
The diabetes vaccine Diamyd is uniquely well positioned to be studied for the prevention of clinical type 1 diabetes considering its strong safety profile and clinical efficacy in recent-onset type 1 diabetes”. The published immunological results are based on the placebo-controlled randomized clinical trial DiAPREV-IT 2, where the safety ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic ...
About Flamingo-01 and GLSI-100 Flamingo-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab ...
As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a clear GAD-specific immune response both in term of antibodies and cell-based reactions in individuals diagnosed with LADA . ...
” About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant ...
The purpose of the assay, when it becomes clinically available in Q1 2023, will be to enable clinicians to monitor patients’ responses to therapies, including in late-stage cancers for which minimal residual disease (MRD) assays may not be as informative or effective. ...